NCT06691217View on ClinicalTrials.gov

Effects of IL-1 Beta Inhibition on Vascular Inflammation in TET2 Clonal Hematopoiesis

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

November 1, 2025

Primary Completion Date

January 1, 2029

Study Completion Date

April 1, 2030

Conditions
Vascular InflammationASCVDASCVD Management
Interventions
DRUG

CANAKINUMAB (ILARIS®)

Participants with and without TET2 CHIP will receive 150mg of canakinumab every 3 months for 4 doses as part of the randomized clinical trial part of this proposal.

DRUG

Saline (NaCl 0,9 %) (placebo)

Participants with and without TET2 CHIP will receive placebo injection every 3 months for 4 doses as part of the randomized clinical trial part of this proposal.

Trial Locations (1)

02114

Massachusetts General Hospital, Boston

All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

collaborator

Broad Institute of MIT and Harvard

OTHER

collaborator

Yale University

OTHER

lead

Massachusetts General Hospital

OTHER